Opus Genetics (NASDAQ:IRD – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01, Zacks reports. The business had revenue of $3.87 million for the quarter, compared to analysts’ expectations of $1.17 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.
Opus Genetics Price Performance
Shares of Opus Genetics stock opened at $1.06 on Friday. Opus Genetics has a 1 year low of $1.06 and a 1 year high of $3.40. The stock has a market capitalization of $33.46 million, a P/E ratio of -0.97 and a beta of 0.22.
Analyst Ratings Changes
Separately, HC Wainwright started coverage on shares of Opus Genetics in a research report on Wednesday. They set a “buy” rating and a $8.00 price target on the stock.
Opus Genetics Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
- Five stocks we like better than Opus Genetics
- Why Are These Companies Considered Blue Chips?
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- What Do S&P 500 Stocks Tell Investors About the Market?
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- 3 Small Caps With Big Return Potential
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
